DDInter810 DDInter119
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Gefitinib {u} (Compound) treats {v} (Disease) lung cancer
Gefitinib {u} (Compound) binds {v} (Gene) CYP2D6
Gefitinib {u} (Compound) upregulates {v} (Gene) ZNF589
Gefitinib {u} (Compound) downregulates {v} (Gene) IFRD2
Gefitinib {u} (Compound) causes {v} (Side Effect) Appetite absent
Gefitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danazol
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Gefitinib (Compound) resembles Bosutinib (Compound)
Gefitinib (Compound) resembles Erlotinib (Compound)
Gefitinib (Compound) treats lung cancer (Disease)
Gefitinib (Compound) binds CYP2D6 (Gene)
Gefitinib (Compound) upregulates ZNF589 (Gene)
Gefitinib (Compound) downregulates IFRD2 (Gene)
Gefitinib (Compound) causes Appetite absent (Side Effect)
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene